PRP（多血小板血漿）市場の2030年までの予測：由来タイプ別、タイプ別、用途別、エンドユーザー別、地域別の世界分析

Stratistics MRCによると、世界のPRP（多血小板血漿）市場は、2024年に8億6,390万米ドルを占め、予測期間中にCAGR 17.3％で成長し、2030年までに22億5,050万米ドルに達すると予想されています。

PRP（多血小板血漿）療法では、患者自身の血漿を濃縮したものを使用して治癒と組織再生を促進します。この治療法は、まず患者から少量の血液を採取し、それを遠心分離機で回転させて血小板と血漿を他の血液成分から分離することから始まる。血小板は血栓形成に不可欠な小さな血液細胞で、体内の治癒プロセスを促進する成長因子を含んでいます。濃縮された血小板リッチ血漿は、患者の関節、腱、皮膚などの患部に注入され、組織の修復と再生を促進します。

2020年にランセット誌に掲載された論文によると、変形性関節症は世界人口の7％、全世界で5億人以上が罹患しており、中でも女性が不釣り合いに罹患しているといいます。

整形外科疾患の増加

PRP（多血小板血漿）療法は、患者自身の血液から血小板を抽出・濃縮し、患部に注入して治癒と組織再生を促進するものです。変形性関節症、腱炎、靭帯損傷などの整形外科疾患は、特に高齢者やスポーツ選手の間でますます一般的になっています。PRPの魅力は、その低侵襲性にあり、手術や長期投薬のような侵襲性の高い治療に代わる選択肢を提供できる可能性にあります。さらに、整形外科におけるPRPの使用は、組織の修復を促進し、痛みを軽減する効果を実証する臨床エビデンスの増加によって裏付けられています。

限られた臨床証拠

PRP（多血小板血漿）市場は、主に、さまざまな医療用途におけるその有効性を裏付ける臨床エビデンスが不十分であることによる制約に直面しています。PRPの人気と潜在的な利点にもかかわらず、確固とした臨床試験と標準化されたプロトコルの欠如が、多くの地域での普及と規制当局の承認を妨げています。臨床医と規制機関は、PRPを自信を持って主流の医療行為に組み込むために、明確な有効性、安全性プロファイル、および長期的転帰を実証する、十分にデザインされた研究を必要としています。しかし、調製方法や患者特有の反応にはばらつきがあるため、普遍的な治療ガイドラインの確立はさらに複雑になっています。

成長するスポーツとフィットネス活動

PRP療法は、治癒を促進するために患者自身の血小板を濃縮して損傷部位に注入するもので、アスリートやフィットネス愛好家の間で人気を博しています。これは主に、腱炎、筋緊張、関節損傷などのスポーツ傷害からの回復を早める可能性があるためです。スポーツやフィットネスに取り組む人が増えるにつれて、効果的で迅速な回復方法に対する需要が高まり、PRP療法の採用が進んでいます。

コストに関する考察

PRP療法には、患者自身の血液から血小板を抽出・濃縮する作業が含まれるが、これには専門的な機器と訓練を受けたスタッフが必要であるため、コストがかさみます。これらの費用は、標準化された価格設定モデルの欠如と保険適用のばらつきによってさらに複雑化し、多くの潜在的な患者にとってPRP治療を手の届かないものにしています。臨床結果にばらつきがあり、特定の疾患に対する有効性に関する決定的なエビデンスがないと考えられているため、ヘルスケアプロバイダーや患者はPRP療法への投資を躊躇してしまいます。

COVID-19の影響：

COVID-19の大流行は、PRP（多血小板血漿）市場に大きな影響を与え、需要と供給の両方の力学に影響を与えました。当初、市場は広範な閉鎖による混乱に直面し、PRP療法を含む選択的手術の減少につながった。多くのクリニックやヘルスケア施設が一時的に閉鎖したりサービスを制限したりしたため、PRP注射のような緊急性のない治療を受ける患者の来院が減少しました。さらに、輸送や流通チェーンにおける物流の課題が、PRP製品の入手をさらに妨げました。しかし、ヘルスケアシステムがパンデミックに適応し、安全な選択的処置を優先するようになると、PRP市場は回復の兆しを見せた。

予測期間中はホモロガス部門が最大になる見込み

ホモロガスセグメントは、その安全性プロファイルと様々な医療＆美容用途における有効性から、予測期間中最大となる見込みです。患者自身の血小板、成長因子、サイトカインを利用することで、PRP療法は組織の修復を促進し、炎症を抑え、自然治癒プロセスを高めることができます。さらに、技術と研究の進歩により、PRPの用途は整形外科にとどまらず、皮膚科、歯科、美容整形にまで拡大し、市場の成長をさらに促進しています。PRP治療の相同性は、患者の転帰を向上させるだけでなく、その安全性と治療可能性に対するヘルスケアプロバイダーや患者の信頼を醸成することで、市場の拡大にも寄与しています。

予測期間中にCAGRが最も高くなると予想されるのは神経分野

神経分野は予測期間中に最も高いCAGRが見込まれます。神経学におけるPRP（多血小板血漿）療法では、治癒と再生を促進するために、患者自身の血漿を濃縮したものを神経系の患部に注入します。PRPには高濃度の血小板が含まれており、組織の修復と再生を刺激する成長因子が豊富に含まれています。神経学では、PRPは末梢神経損傷、脊髄損傷、パーキンソン病やアルツハイマー病などの神経変性疾患などの治療に有望視されています。この治療法は、身体の自然治癒プロセスを促進し、炎症を抑え、損傷した神経組織の機能を回復させる可能性があります。

最大のシェアを占める地域

北米地域が推定期間で最大の市場シェアを占めています。高齢者人口が増加するにつれて、変形性関節症、慢性腱症、その他の筋骨格系障害など、PRP療法で対処できる可能性のある疾患の有病率も増加しています。患者自身の血液に由来するPRPは、組織の修復を刺激し炎症を軽減する能力があるとされるため、ますます求められるようになっており、この地域全体で侵襲的な処置を嫌う高齢者にとって特に魅力的な非外科的選択肢を提供しています。

CAGRが最も高い地域：

欧州地域は、予測期間中に有益な成長を示すと予測されます。政府の規制は、PRP療法が臨床的に販売または使用される前に、厳格な有効性と安全性の基準を満たすことを保証しています。厳格な監視を実施することで、欧州当局は、汚染や一貫性のない製品品質など、PRP治療に関連するリスクを軽減しています。さらに、規制の枠組みはPRP技術の研究開発を促進し、イノベーションを促進し、地域全体の治療成績を向上させる。PRP規制に対する構造化されたアプローチは、患者の健康を守るだけでなく、ヘルスケアプロバイダーと患者の信頼性を高め、地域全体のさまざまな医療分野でのPRP療法の幅広い採用を促しています。

無料のカスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレーヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査情報源
  • 1次調査情報源
  • 2次調査情報源
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 用途分析
• エンドユーザー分析
• 新興市場
• COVID-19の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界のPRP（多血小板血漿）市場：由来タイプ別

• 自家
• 相同
• 同種

第6章 世界のPRP（多血小板血漿）市場：タイプ別

• 白血球を多く含むPRP
• 白血球を多く含むフィブリン
• その他のタイプ

第7章 世界のPRP（多血小板血漿）市場：用途別

• 心臓病学
• 美容外科・皮膚科
• 神経学
• 整形外科
• 眼科
• その他の用途

第8章 世界のPRP（多血小板血漿）市場：エンドユーザー別

• 病院
• 研究機関
• その他のエンドユーザー

第9章 世界のPRP（多血小板血漿）市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第10章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品発売
• 事業拡大
• その他の主要戦略

第11章 企業プロファイリング

• AdiStem Ltd
• Arthrex, Inc
• Cellular Biomedicine Group, Inc
• Cesca Therapeutics Inc
• EmCyte Corporation
• Exactech, Inc
• Global Human Biomaterials Inc
• Harvest Technologies
• Nuo Therapeutics, Inc
• Stryker Corporation
• Synthetic Blood International, Inc
• Terumo Corporation

List of Tables

• Table 1 Global Platelet Rich Plasma (PRP) Market Outlook, By Region (2022-2030) ($MN)
• Table 2 Global Platelet Rich Plasma (PRP) Market Outlook, By Origin Type (2022-2030) ($MN)
• Table 3 Global Platelet Rich Plasma (PRP) Market Outlook, By Autologous (2022-2030) ($MN)
• Table 4 Global Platelet Rich Plasma (PRP) Market Outlook, By Homologous (2022-2030) ($MN)
• Table 5 Global Platelet Rich Plasma (PRP) Market Outlook, By Allogeneic (2022-2030) ($MN)
• Table 6 Global Platelet Rich Plasma (PRP) Market Outlook, By Type (2022-2030) ($MN)
• Table 7 Global Platelet Rich Plasma (PRP) Market Outlook, By Leukocyte-rich PRP (2022-2030) ($MN)
• Table 8 Global Platelet Rich Plasma (PRP) Market Outlook, By Leukocyte-rich Fibrin (2022-2030) ($MN)
• Table 9 Global Platelet Rich Plasma (PRP) Market Outlook, By Other Types (2022-2030) ($MN)
• Table 10 Global Platelet Rich Plasma (PRP) Market Outlook, By Application (2022-2030) ($MN)
• Table 11 Global Platelet Rich Plasma (PRP) Market Outlook, By Cardiology (2022-2030) ($MN)
• Table 12 Global Platelet Rich Plasma (PRP) Market Outlook, By Cosmetic Surgery and Dermatology (2022-2030) ($MN)
• Table 13 Global Platelet Rich Plasma (PRP) Market Outlook, By Neurology (2022-2030) ($MN)
• Table 14 Global Platelet Rich Plasma (PRP) Market Outlook, By Orthopedics (2022-2030) ($MN)
• Table 15 Global Platelet Rich Plasma (PRP) Market Outlook, By Ophthalmology (2022-2030) ($MN)
• Table 16 Global Platelet Rich Plasma (PRP) Market Outlook, By Other Applications (2022-2030) ($MN)
• Table 17 Global Platelet Rich Plasma (PRP) Market Outlook, By End User (2022-2030) ($MN)
• Table 18 Global Platelet Rich Plasma (PRP) Market Outlook, By Hospitals (2022-2030) ($MN)
• Table 19 Global Platelet Rich Plasma (PRP) Market Outlook, By Research Institutes (2022-2030) ($MN)
• Table 20 Global Platelet Rich Plasma (PRP) Market Outlook, By Other End Users (2022-2030) ($MN)
• Table 21 North America Platelet Rich Plasma (PRP) Market Outlook, By Country (2022-2030) ($MN)
• Table 22 North America Platelet Rich Plasma (PRP) Market Outlook, By Origin Type (2022-2030) ($MN)
• Table 23 North America Platelet Rich Plasma (PRP) Market Outlook, By Autologous (2022-2030) ($MN)
• Table 24 North America Platelet Rich Plasma (PRP) Market Outlook, By Homologous (2022-2030) ($MN)
• Table 25 North America Platelet Rich Plasma (PRP) Market Outlook, By Allogeneic (2022-2030) ($MN)
• Table 26 North America Platelet Rich Plasma (PRP) Market Outlook, By Type (2022-2030) ($MN)
• Table 27 North America Platelet Rich Plasma (PRP) Market Outlook, By Leukocyte-rich PRP (2022-2030) ($MN)
• Table 28 North America Platelet Rich Plasma (PRP) Market Outlook, By Leukocyte-rich Fibrin (2022-2030) ($MN)
• Table 29 North America Platelet Rich Plasma (PRP) Market Outlook, By Other Types (2022-2030) ($MN)
• Table 30 North America Platelet Rich Plasma (PRP) Market Outlook, By Application (2022-2030) ($MN)
• Table 31 North America Platelet Rich Plasma (PRP) Market Outlook, By Cardiology (2022-2030) ($MN)
• Table 32 North America Platelet Rich Plasma (PRP) Market Outlook, By Cosmetic Surgery and Dermatology (2022-2030) ($MN)
• Table 33 North America Platelet Rich Plasma (PRP) Market Outlook, By Neurology (2022-2030) ($MN)
• Table 34 North America Platelet Rich Plasma (PRP) Market Outlook, By Orthopedics (2022-2030) ($MN)
• Table 35 North America Platelet Rich Plasma (PRP) Market Outlook, By Ophthalmology (2022-2030) ($MN)
• Table 36 North America Platelet Rich Plasma (PRP) Market Outlook, By Other Applications (2022-2030) ($MN)
• Table 37 North America Platelet Rich Plasma (PRP) Market Outlook, By End User (2022-2030) ($MN)
• Table 38 North America Platelet Rich Plasma (PRP) Market Outlook, By Hospitals (2022-2030) ($MN)
• Table 39 North America Platelet Rich Plasma (PRP) Market Outlook, By Research Institutes (2022-2030) ($MN)
• Table 40 North America Platelet Rich Plasma (PRP) Market Outlook, By Other End Users (2022-2030) ($MN)
• Table 41 Europe Platelet Rich Plasma (PRP) Market Outlook, By Country (2022-2030) ($MN)
• Table 42 Europe Platelet Rich Plasma (PRP) Market Outlook, By Origin Type (2022-2030) ($MN)
• Table 43 Europe Platelet Rich Plasma (PRP) Market Outlook, By Autologous (2022-2030) ($MN)
• Table 44 Europe Platelet Rich Plasma (PRP) Market Outlook, By Homologous (2022-2030) ($MN)
• Table 45 Europe Platelet Rich Plasma (PRP) Market Outlook, By Allogeneic (2022-2030) ($MN)
• Table 46 Europe Platelet Rich Plasma (PRP) Market Outlook, By Type (2022-2030) ($MN)
• Table 47 Europe Platelet Rich Plasma (PRP) Market Outlook, By Leukocyte-rich PRP (2022-2030) ($MN)
• Table 48 Europe Platelet Rich Plasma (PRP) Market Outlook, By Leukocyte-rich Fibrin (2022-2030) ($MN)
• Table 49 Europe Platelet Rich Plasma (PRP) Market Outlook, By Other Types (2022-2030) ($MN)
• Table 50 Europe Platelet Rich Plasma (PRP) Market Outlook, By Application (2022-2030) ($MN)
• Table 51 Europe Platelet Rich Plasma (PRP) Market Outlook, By Cardiology (2022-2030) ($MN)
• Table 52 Europe Platelet Rich Plasma (PRP) Market Outlook, By Cosmetic Surgery and Dermatology (2022-2030) ($MN)
• Table 53 Europe Platelet Rich Plasma (PRP) Market Outlook, By Neurology (2022-2030) ($MN)
• Table 54 Europe Platelet Rich Plasma (PRP) Market Outlook, By Orthopedics (2022-2030) ($MN)
• Table 55 Europe Platelet Rich Plasma (PRP) Market Outlook, By Ophthalmology (2022-2030) ($MN)
• Table 56 Europe Platelet Rich Plasma (PRP) Market Outlook, By Other Applications (2022-2030) ($MN)
• Table 57 Europe Platelet Rich Plasma (PRP) Market Outlook, By End User (2022-2030) ($MN)
• Table 58 Europe Platelet Rich Plasma (PRP) Market Outlook, By Hospitals (2022-2030) ($MN)
• Table 59 Europe Platelet Rich Plasma (PRP) Market Outlook, By Research Institutes (2022-2030) ($MN)
• Table 60 Europe Platelet Rich Plasma (PRP) Market Outlook, By Other End Users (2022-2030) ($MN)
• Table 61 Asia Pacific Platelet Rich Plasma (PRP) Market Outlook, By Country (2022-2030) ($MN)
• Table 62 Asia Pacific Platelet Rich Plasma (PRP) Market Outlook, By Origin Type (2022-2030) ($MN)
• Table 63 Asia Pacific Platelet Rich Plasma (PRP) Market Outlook, By Autologous (2022-2030) ($MN)
• Table 64 Asia Pacific Platelet Rich Plasma (PRP) Market Outlook, By Homologous (2022-2030) ($MN)
• Table 65 Asia Pacific Platelet Rich Plasma (PRP) Market Outlook, By Allogeneic (2022-2030) ($MN)
• Table 66 Asia Pacific Platelet Rich Plasma (PRP) Market Outlook, By Type (2022-2030) ($MN)
• Table 67 Asia Pacific Platelet Rich Plasma (PRP) Market Outlook, By Leukocyte-rich PRP (2022-2030) ($MN)
• Table 68 Asia Pacific Platelet Rich Plasma (PRP) Market Outlook, By Leukocyte-rich Fibrin (2022-2030) ($MN)
• Table 69 Asia Pacific Platelet Rich Plasma (PRP) Market Outlook, By Other Types (2022-2030) ($MN)
• Table 70 Asia Pacific Platelet Rich Plasma (PRP) Market Outlook, By Application (2022-2030) ($MN)
• Table 71 Asia Pacific Platelet Rich Plasma (PRP) Market Outlook, By Cardiology (2022-2030) ($MN)
• Table 72 Asia Pacific Platelet Rich Plasma (PRP) Market Outlook, By Cosmetic Surgery and Dermatology (2022-2030) ($MN)
• Table 73 Asia Pacific Platelet Rich Plasma (PRP) Market Outlook, By Neurology (2022-2030) ($MN)
• Table 74 Asia Pacific Platelet Rich Plasma (PRP) Market Outlook, By Orthopedics (2022-2030) ($MN)
• Table 75 Asia Pacific Platelet Rich Plasma (PRP) Market Outlook, By Ophthalmology (2022-2030) ($MN)
• Table 76 Asia Pacific Platelet Rich Plasma (PRP) Market Outlook, By Other Applications (2022-2030) ($MN)
• Table 77 Asia Pacific Platelet Rich Plasma (PRP) Market Outlook, By End User (2022-2030) ($MN)
• Table 78 Asia Pacific Platelet Rich Plasma (PRP) Market Outlook, By Hospitals (2022-2030) ($MN)
• Table 79 Asia Pacific Platelet Rich Plasma (PRP) Market Outlook, By Research Institutes (2022-2030) ($MN)
• Table 80 Asia Pacific Platelet Rich Plasma (PRP) Market Outlook, By Other End Users (2022-2030) ($MN)
• Table 81 South America Platelet Rich Plasma (PRP) Market Outlook, By Country (2022-2030) ($MN)
• Table 82 South America Platelet Rich Plasma (PRP) Market Outlook, By Origin Type (2022-2030) ($MN)
• Table 83 South America Platelet Rich Plasma (PRP) Market Outlook, By Autologous (2022-2030) ($MN)
• Table 84 South America Platelet Rich Plasma (PRP) Market Outlook, By Homologous (2022-2030) ($MN)
• Table 85 South America Platelet Rich Plasma (PRP) Market Outlook, By Allogeneic (2022-2030) ($MN)
• Table 86 South America Platelet Rich Plasma (PRP) Market Outlook, By Type (2022-2030) ($MN)
• Table 87 South America Platelet Rich Plasma (PRP) Market Outlook, By Leukocyte-rich PRP (2022-2030) ($MN)
• Table 88 South America Platelet Rich Plasma (PRP) Market Outlook, By Leukocyte-rich Fibrin (2022-2030) ($MN)
• Table 89 South America Platelet Rich Plasma (PRP) Market Outlook, By Other Types (2022-2030) ($MN)
• Table 90 South America Platelet Rich Plasma (PRP) Market Outlook, By Application (2022-2030) ($MN)
• Table 91 South America Platelet Rich Plasma (PRP) Market Outlook, By Cardiology (2022-2030) ($MN)
• Table 92 South America Platelet Rich Plasma (PRP) Market Outlook, By Cosmetic Surgery and Dermatology (2022-2030) ($MN)
• Table 93 South America Platelet Rich Plasma (PRP) Market Outlook, By Neurology (2022-2030) ($MN)
• Table 94 South America Platelet Rich Plasma (PRP) Market Outlook, By Orthopedics (2022-2030) ($MN)
• Table 95 South America Platelet Rich Plasma (PRP) Market Outlook, By Ophthalmology (2022-2030) ($MN)
• Table 96 South America Platelet Rich Plasma (PRP) Market Outlook, By Other Applications (2022-2030) ($MN)
• Table 97 South America Platelet Rich Plasma (PRP) Market Outlook, By End User (2022-2030) ($MN)
• Table 98 South America Platelet Rich Plasma (PRP) Market Outlook, By Hospitals (2022-2030) ($MN)
• Table 99 South America Platelet Rich Plasma (PRP) Market Outlook, By Research Institutes (2022-2030) ($MN)
• Table 100 South America Platelet Rich Plasma (PRP) Market Outlook, By Other End Users (2022-2030) ($MN)
• Table 101 Middle East & Africa Platelet Rich Plasma (PRP) Market Outlook, By Country (2022-2030) ($MN)
• Table 102 Middle East & Africa Platelet Rich Plasma (PRP) Market Outlook, By Origin Type (2022-2030) ($MN)
• Table 103 Middle East & Africa Platelet Rich Plasma (PRP) Market Outlook, By Autologous (2022-2030) ($MN)
• Table 104 Middle East & Africa Platelet Rich Plasma (PRP) Market Outlook, By Homologous (2022-2030) ($MN)
• Table 105 Middle East & Africa Platelet Rich Plasma (PRP) Market Outlook, By Allogeneic (2022-2030) ($MN)
• Table 106 Middle East & Africa Platelet Rich Plasma (PRP) Market Outlook, By Type (2022-2030) ($MN)
• Table 107 Middle East & Africa Platelet Rich Plasma (PRP) Market Outlook, By Leukocyte-rich PRP (2022-2030) ($MN)
• Table 108 Middle East & Africa Platelet Rich Plasma (PRP) Market Outlook, By Leukocyte-rich Fibrin (2022-2030) ($MN)
• Table 109 Middle East & Africa Platelet Rich Plasma (PRP) Market Outlook, By Other Types (2022-2030) ($MN)
• Table 110 Middle East & Africa Platelet Rich Plasma (PRP) Market Outlook, By Application (2022-2030) ($MN)
• Table 111 Middle East & Africa Platelet Rich Plasma (PRP) Market Outlook, By Cardiology (2022-2030) ($MN)
• Table 112 Middle East & Africa Platelet Rich Plasma (PRP) Market Outlook, By Cosmetic Surgery and Dermatology (2022-2030) ($MN)
• Table 113 Middle East & Africa Platelet Rich Plasma (PRP) Market Outlook, By Neurology (2022-2030) ($MN)
• Table 114 Middle East & Africa Platelet Rich Plasma (PRP) Market Outlook, By Orthopedics (2022-2030) ($MN)
• Table 115 Middle East & Africa Platelet Rich Plasma (PRP) Market Outlook, By Ophthalmology (2022-2030) ($MN)
• Table 116 Middle East & Africa Platelet Rich Plasma (PRP) Market Outlook, By Other Applications (2022-2030) ($MN)
• Table 117 Middle East & Africa Platelet Rich Plasma (PRP) Market Outlook, By End User (2022-2030) ($MN)
• Table 118 Middle East & Africa Platelet Rich Plasma (PRP) Market Outlook, By Hospitals (2022-2030) ($MN)
• Table 119 Middle East & Africa Platelet Rich Plasma (PRP) Market Outlook, By Research Institutes (2022-2030) ($MN)
• Table 120 Middle East & Africa Platelet Rich Plasma (PRP) Market Outlook, By Other End Users (2022-2030) ($MN)

According to Stratistics MRC, the Global Platelet Rich Plasma (PRP) Market is accounted for $863.9 million in 2024 and is expected to reach $2,250.5 million by 2030 growing at a CAGR of 17.3% during the forecast period. Platelet Rich Plasma (PRP) therapy involves using a concentrated form of a patient's own blood plasma to promote healing and tissue regeneration. This procedure begins with drawing a small amount of blood from the patient, which is then spun in a centrifuge to separate the platelets and plasma from other blood components. Platelets are tiny blood cells crucial for clot formation and contain growth factors that facilitate healing processes in the body. Once concentrated, this platelet-rich plasma is injected back into the patient's affected area, such as joints, tendons, or skin, where it stimulates tissue repair and regeneration.

According to the article published in the Lancet Journal in 2020, osteoarthritis affects 7% of the global population, more than 500 million people worldwide, with women disproportionately affected by the condition.

Market Dynamics:

Driver:

Increasing prevalence of orthopedic disorders

Platelet Rich Plasma therapy involves the extraction and concentration of platelets from a patient's own blood, which are then injected into the affected area to accelerate healing and tissue regeneration. Orthopedic conditions such as osteoarthritis, tendonitis, and ligament injuries are increasingly common, particularly among aging populations and athletes. PRP's appeal lies in its minimally invasive nature and potential to offer an alternative to more invasive treatments like surgery or long-term medication. Moreover, its use in orthopedics is supported by a growing body of clinical evidence demonstrating its effectiveness in promoting tissue repair and reducing pain.

Restraint:

Limited clinical evidence

The Platelet Rich Plasma (PRP) market faces limitations primarily due to insufficient clinical evidence supporting its efficacy across various medical applications. Despite its popularity and potential benefits, the lack of robust clinical trials and standardized protocols hinders widespread adoption and regulatory approval in many regions. Clinicians and regulatory bodies require well-designed studies demonstrating clear efficacy, safety profiles, and long-term outcomes to confidently integrate PRP into mainstream medical practices. However, variability in preparation methods and patient-specific responses further complicate the establishment of universal treatment guidelines.

Opportunity:

Growing sports and physical fitness activities

PRP therapy, which involves injecting a concentration of a patient's own platelets into injured areas to promote healing, has gained popularity among athletes and fitness enthusiasts. This is primarily due to its potential to accelerate recovery from sports injuries such as tendonitis, muscle strains, and joint injuries. As more individuals engage in sports and fitness routines, there is an increasing demand for effective and swift recovery methods, driving the adoption of PRP therapy.

Threat:

Cost considerations

PRP therapy involves extracting and concentrating platelets from a patient's own blood, which requires specialized equipment and trained personnel, thus driving up costs. These expenses are further compounded by the lack of standardized pricing models and insurance coverage variability, making PRP treatments unaffordable for many potential patients. The variability in clinical outcomes and the perceived lack of definitive evidence regarding its efficacy for certain conditions can deter healthcare providers and patients from investing in PRP therapy.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the Platelet Rich Plasma (PRP) market, affecting both demand and supply dynamics. Initially, the market faced disruptions due to widespread lockdowns, which led to a reduction in elective procedures, including those involving PRP therapy. Many clinics and healthcare facilities temporarily closed or limited their services, causing a decline in patient visits for non-urgent treatments like PRP injections. Moreover, logistical challenges in transportation and distribution chains further hindered the availability of PRP products. However, as healthcare systems adapted to the pandemic and began to prioritize safe elective procedures, the PRP market showed signs of recovery.

The Homologous segment is expected to be the largest during the forecast period

Homologous segment is expected to be the largest during the forecast period due to its safety profile and effectiveness in various medical and aesthetic applications. By utilizing the patient's own platelets, growth factors, and cytokines, PRP therapies can promote tissue repair, reduce inflammation, and enhance healing processes naturally. Moreover, advancements in technology and research have expanded the applications of PRP beyond orthopedics to dermatology, dentistry, and cosmetic procedures, further driving market growth. The homologous nature of PRP treatments not only enhances patient outcomes but also contributes to the market's expansion by fostering confidence among healthcare providers and patients alike in its safety and therapeutic potential.

The Neurology segment is expected to have the highest CAGR during the forecast period

Neurology segment is expected to have the highest CAGR during the forecast period. Platelet Rich Plasma (PRP) therapy in neurology involves injecting a concentrated form of a patient's own blood plasma into affected areas of the nervous system to promote healing and regeneration. PRP contains a high concentration of platelets, which are rich in growth factors that stimulate tissue repair and regeneration. In neurology, PRP has shown promise in treating conditions such as peripheral nerve injuries, spinal cord injuries, and neurodegenerative diseases like Parkinson's and Alzheimer's. The therapy aims to enhance the body's natural healing processes, reduce inflammation, and potentially restore function to damaged nerve tissues.

Region with largest share:

North America region commanded the largest market share over the extrapolated period. As the elderly demographic grows, so does the prevalence of conditions such as osteoarthritis, chronic tendinopathy, and other musculoskeletal disorders that PRP therapy can potentially address across the region. PRP, derived from a patient's own blood, is increasingly sought after for its purported ability to stimulate tissue repair and reduce inflammation, offering a non-surgical option particularly appealing to older individuals wary of invasive procedures throughout the region.

Region with highest CAGR:

Europe region is estimated to witness profitable growth during the forecasted period. Government regulations ensure that PRP therapies meet strict efficacy and safety criteria before they can be marketed or used clinically. By enforcing rigorous oversight, European authorities mitigate risks associated with PRP treatments, such as contamination and inconsistent product quality. Moreover, regulatory frameworks promote research and development in PRP technologies, fostering innovation and improving treatment outcomes across the region. The structured approach to PRP regulation not only safeguards patient health but also enhances confidence among healthcare providers and patients alike, encouraging broader adoption of PRP therapies across various medical disciplines throughout the region.

Key players in the market

Some of the key players in Platelet Rich Plasma (PRP) market include AdiStem Ltd, Arthrex, Inc, Cellular Biomedicine Group, Inc, Cesca Therapeutics Inc, EmCyte Corporation, Exactech, Inc, Global Human Biomaterials Inc, Harvest Technologies, Nuo Therapeutics, Inc, Stryker Corporation, Synthetic Blood International, Inc and Terumo Corporation.

Key Developments:

In December 2023, Hairline International Hair and Skin Clinic, the hair clinic, announced the launch of an advanced hair regeneration therapy called Sonicated PRP, based on groundbreaking research utilizing platelet-rich plasma (PRP). The cutting-edge treatment, aims to revolutionize hair follicle activation and regeneration.

In January 2023, RegenOrthoSport, an orthopedic clinic, in Mumbai, Maharashtra, announced that it had received an approval from the National Ethics Committee Registry for Biomedical and Health Research (NECRBHR), under the Ministry of Health and Family Welfare for the use of Autologous Bone Marrow Aspirate Concentrate (BMAC) and Platelet Rich Plasma (PRP) on patients affected with musculoskeletal disorders

In May 2022, Ester Medical, a pharmaceutical company announced that it had signed an agreement with Aesthetic Management for exclusive long-term marketing and distribution of Eclipse PRP and Tropocells in the U.S. market.

Origin Types Covered:

• Autologous
• Homologous
• Allogeneic

Types Covered:

• Leukocyte-rich PRP
• Leukocyte-rich Fibrin
• Other Types

Applications Covered:

• Cardiology
• Cosmetic Surgery and Dermatology
• Neurology
• Orthopedics
• Ophthalmology
• Other Applications

End Users Covered:

• Hospitals
• Research Institutes
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Platelet Rich Plasma (PRP) Market, By Origin Type

• 5.1 Introduction
• 5.2 Autologous
• 5.3 Homologous
• 5.4 Allogeneic

6 Global Platelet Rich Plasma (PRP) Market, By Type

• 6.1 Introduction
• 6.2 Leukocyte-rich PRP
• 6.3 Leukocyte-rich Fibrin
• 6.4 Other Types

7 Global Platelet Rich Plasma (PRP) Market, By Application

• 7.1 Introduction
• 7.2 Cardiology
• 7.3 Cosmetic Surgery and Dermatology
• 7.4 Neurology
• 7.5 Orthopedics
• 7.6 Ophthalmology
• 7.7 Other Applications

8 Global Platelet Rich Plasma (PRP) Market, By End User

• 8.1 Introduction
• 8.2 Hospitals
• 8.3 Research Institutes
• 8.4 Other End Users

9 Global Platelet Rich Plasma (PRP) Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 AdiStem Ltd
• 11.2 Arthrex, Inc
• 11.3 Cellular Biomedicine Group, Inc
• 11.4 Cesca Therapeutics Inc
• 11.5 EmCyte Corporation
• 11.6 Exactech, Inc
• 11.7 Global Human Biomaterials Inc
• 11.8 Harvest Technologies
• 11.9 Nuo Therapeutics, Inc
• 11.10 Stryker Corporation
• 11.11 Synthetic Blood International, Inc
• 11.12 Terumo Corporation